🔗 Share this article Users Stopping Anti-Obesity Medications Gain Back Weight Far More Rapidly Than Those on Conventional Diets Weight management often requires ongoing approaches. A recent study suggests that patients who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight much more quickly than those who end traditional diet and exercise programs. Research printed in a leading medical journal demonstrates that while overweight individuals often shed a large proportion of their body weight while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month after stopping. "People using such medications should be aware of the danger of rapid rebound weight gain when the medication is stopped," warns expert Dr. Susan Jebb. This pace of recovery implies a return to original weight within about a year and a half. Comparing Therapies The analysis, which looked at 37 of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with other pills. Scientists emphasize that people who lose weight through dieting typically experience a slower creep back—perhaps 0.1 kg a month—post-intervention. Understanding the Rapid Rebound Doctors suggest the way of the jabs explains the heightened weight return. The injections mimic a body's own chemical called GLP-1, which helps regulate hunger. "Long-term administration of GLP-1 levels far above than normal might result in the body to produce less of its own natural GLP-1, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist. "Withdrawal of this hormone supplement means appetite is no longer kept in check, making excessive eating much more probable." An Ongoing Condition? The NHS suggest the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications. Many experts argue that, due to the likelihood of weight regain, the treatment might need to be long-term. This view is supported by drug manufacturers, who note that the results "emphasize the chronic nature of obesity," comparing it to managing diseases like high blood pressure. User Experiences Individuals who have stopped the jabs explain a intense return of appetite. "I experienced something that goes on and you become ravenous," said a patient. This difficulty is worsened if individuals have not established permanent lifestyle or habit changes during therapy. Significant Adoption Figures show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial. Use is more common among women than men. The middle-aged demographic shows the highest level of interest. A large proportion access the drugs through private prescriptions rather than public health services. In conclusion, clinicians emphasize that while these medications are effective agents for weight loss, they are not a standalone fix and maintained weight loss hinges on integrated lifestyle management.
Weight management often requires ongoing approaches. A recent study suggests that patients who discontinue blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight much more quickly than those who end traditional diet and exercise programs. Research printed in a leading medical journal demonstrates that while overweight individuals often shed a large proportion of their body weight while using the jabs, the weight comes back at an estimated rate of nearly a kilo each month after stopping. "People using such medications should be aware of the danger of rapid rebound weight gain when the medication is stopped," warns expert Dr. Susan Jebb. This pace of recovery implies a return to original weight within about a year and a half. Comparing Therapies The analysis, which looked at 37 of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with other pills. Scientists emphasize that people who lose weight through dieting typically experience a slower creep back—perhaps 0.1 kg a month—post-intervention. Understanding the Rapid Rebound Doctors suggest the way of the jabs explains the heightened weight return. The injections mimic a body's own chemical called GLP-1, which helps regulate hunger. "Long-term administration of GLP-1 levels far above than normal might result in the body to produce less of its own natural GLP-1, and may also diminish responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist. "Withdrawal of this hormone supplement means appetite is no longer kept in check, making excessive eating much more probable." An Ongoing Condition? The NHS suggest the jabs for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications. Many experts argue that, due to the likelihood of weight regain, the treatment might need to be long-term. This view is supported by drug manufacturers, who note that the results "emphasize the chronic nature of obesity," comparing it to managing diseases like high blood pressure. User Experiences Individuals who have stopped the jabs explain a intense return of appetite. "I experienced something that goes on and you become ravenous," said a patient. This difficulty is worsened if individuals have not established permanent lifestyle or habit changes during therapy. Significant Adoption Figures show that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial. Use is more common among women than men. The middle-aged demographic shows the highest level of interest. A large proportion access the drugs through private prescriptions rather than public health services. In conclusion, clinicians emphasize that while these medications are effective agents for weight loss, they are not a standalone fix and maintained weight loss hinges on integrated lifestyle management.